PharmaCyte Biotech, Inc. PMCB
NASDAQ
| 07/31/2026 | 04/30/2026 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 5.20% | -55.56% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 4.67% | -54.59% | |||
| Operating Income | -4.67% | 54.59% | |||
| Income Before Tax | -15.66% | -688.22% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -15.66% | -688.22% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -15.66% | -688.22% | |||
| EBIT | -4.67% | 54.59% | |||
| EBITDA | -- | -- | |||
| EPS Basic | -17.87% | -172.14% | |||
| Normalized Basic EPS | -59.30% | 255.67% | |||
| EPS Diluted | -17.87% | -172.14% | |||
| Normalized Diluted EPS | -59.30% | 255.67% | |||
| Average Basic Shares Outstanding | 0.72% | 15.07% | |||
| Average Diluted Shares Outstanding | 0.72% | 15.07% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | 0.14% | -1.14% | |||